7 Aug 2022
AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS
Author: admintech | Filed under: Press ReleaseFirst Data From LUMAKRAS Plus Immunotherapy and LUMAKRAS Plus SHP2 Inhibitor Combinations Show Clinical Activity and Support Ongoing Investigation Updated Phase 1 Tarlatamab Data Reinforce Potential of BiTE® Therapy in Small Cell Lung Cancer THOUSAND OAKS, Calif., Aug. 7, 2022…